News & Events

Meet Our Head of Cell Technologies: Dr. Paul de Sousa

Dr. Paul de Sousa Appointed as Head of Cell Technologies at Stemmatters, Bringing Expertise in Developmental Biology & Pluripotent Stem Cell Science and Technologies

June 13, 2023 – Guimarães, Portugal  Stemmatters, a leading biotechnology company specializing in the development and manufacturing of biomaterials & stem cell-based therapies, is pleased to announce the appointment of Dr. Paul de Sousa as the new Head of Cell Technologies. Dr. de Sousa's extensive experience in developmental biology & pluripotent stem cells (PSC) science and technologies makes him a valuable addition to Stemmatters' dynamic team.

Dr. Paul de Sousa brings a wealth of knowledge in the field of regenerative medicine with over 25 years of experience in mammalian development and stem cell science and technologies. This has included advancing state of the art understanding and innovations in in vitro systems for assisted conception, parthenogenesis, and somatic cell nuclear transfer as applied in animal transgenesis, and derivation, expansion, banking, differentiation and characterisation of human embryonic (ESCs) and induced pluripotent (iPSCs) for discovery and clinical applications. Prior to joining Stemmatters, Dr. de Sousa held senior leadership positions at the Roslin Institute and University of Edinburgh. He co-founded and served as CSO for Roslin Cells Ltd. leading to the establishment of Scotland’s PSC manufacturing capability; clinical grade cell lines currently serving as source material for advanced cell therapy initiatives by multiple groups across Europe; and the European Bank for Induced Stem Cells (EBISC). He has successfully collaborated with renowned institutions worldwide, fostering strong multi-disciplinary partnerships across public and private sector industries, and government regulatory agencies. Dr. de Sousa has over 100 peer-reviewed publications and filed patents that have been commercially licensed. In addition, he has trained or directly line managed over 50 post-doctoral, graduate, undergraduate, technical scientists, and administrative associates. Dr. de Sousa has also served on the scientific advisory committees of private and public sector organisations institutions, the latter including the UK Department of Health Human Fertilisation and Embryology Authority and Safety of Blood Tissues and Organs.

As the Head of Cell Technologies at Stemmatters, Dr. de Sousa will play a pivotal role in the company's efforts to accelerate the advancement of the regenerative medicine field. Stemmatters is focused on consolidating experience and expertise in biomaterials and PSCs and on harnessing its potential for the development of pioneering technologies. His leadership and deep understanding of mammalian development and PSC science, banking and manufacturing will be instrumental in guiding Stemmatters' strategic initiatives, as the company continues to explore new avenues in regenerative medicine. With Dr. de Sousa leading the Cell Technologies division, Stemmatters strengthens its position in providing process and analytical development, as well as regulatory compliant manufacturing services to support customers unlocking the potential of advanced therapies and realizing tomorrow´ medicines.

“Stemmatters’ depth and breadth of expertise in biomaterials, biologics and adult tissue derived stem cells uniquely position it as a competitive go to European CDMO”, said Dr de Sousa. “I am very excited to join its team to further augment its capacity to attract clients and partners in the translation of their prior research into the next generation of advanced therapeutics for human disease and ageing."

“We are honored to have Paul joining our leadership team at Stemmatters." said Rui A. Sousa, CEO and Chairman of Stemmatters, “His exceptional track record and industry knowledge will undoubtedly make a significant impact on our organization and strengthen our company's position in the market.”

About Stemmatters:

Stemmatters is a CDMO based in Portugal offering fully integrated and cost-competitive services to the advanced therapy community. With state-of-the-art facilities and a team of highly skilled scientists and technicians, Stemmatters is committed to providing its customers with tailored, reliable and cost-effective services to support the non-clinical and clinical development of advanced therapies for unmet medical needs.

Stemmatters Contact:

Rui A. Sousa, CEO
+351 253 165 230 | rasousa@stemmatters.com